That’s what makes the factoid in #msg-64637084 even more surprising: one would think that the in-house drugs are being measured from an earlier stage, on average, than the in-licensed drugs, and hence they should have a higher failure rate.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”